|
1
|
Ferlay J, Colombet M, Soerjomataram I,
Dyba T, Randi G, Bettio M, Gavin A, Visser O and Bray F: Cancer
incidence and mortality patterns in Europe: Estimates for 40
countries and 25 major cancers in 2018. Eur J Cancer. 103:356–387.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Wu C, Li M, Meng H, Liu Y, Niu W, Zhou Y,
Zhao R, Duan Y, Zeng Z, Li X, et al: Analysis of status and
countermeasures of cancer incidence and mortality in China. Sci
China Life Sci. 62:640–647. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Nasim F, Sabath BF and Eapen GA: Lung
cancer. Med Clin North Am. 103:463–473. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Relli V, Trerotola M, Guerra E and Alberti
S: Abandoning the notion of non-small cell lung cancer. Trends Mol
Med. 25:585–594. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Noronha V, Patil VM, Joshi A, Menon N,
Chougule A, Mahajan A, Janu A, Purandare N, Kumar R, More S, et al:
Gefitinib versus gefitinib plus pemetrexed and carboplatin
chemotherapy in EGFR-mutated lung cancer. J Clin Oncol. 38:124–136.
2020. View Article : Google Scholar
|
|
6
|
Gibson AJW, D'Silva A, Elegbede AA, Tudor
RA, Dean ML, Bebb DG and Hao D: Impact of Asian ethnicity on
outcome in metastatic EGFR-mutant non-small cell lung cancer. Asia
Pac J Clin Oncol. 15:343–352. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Harrison PT, Vyse S and Huang PH: Rare
epidermal growth factor receptor (EGFR) mutations in non-small cell
lung cancer. Semin Cancer Biol. 61:167–179. 2020. View Article : Google Scholar :
|
|
8
|
Gelatti ACZ, Drilon A and Santini FC:
Optimizing the sequencing of tyrosine kinase inhibitors (TKIs) in
epidermal growth factor receptor (EGFR) mutation-positive non-small
cell lung cancer (NSCLC). Lung Cancer. 137:113–122. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Dong ZY, Zhang JT, Liu SY, Su J, Zhang C,
Xie Z, Zhou Q, Tu HY, Xu CR, Yan LX, et al: EGFR mutation
correlates with uninflamed phenotype and weak immunogenicity,
causing impaired response to PD-1 blockade in non-small cell lung
cancer. Oncoimmunology. 6:e13561452017. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Zhong C, Lang Q, Yu J, Wu S, Xu F and Tian
Y: Phenotypical and potential functional characteristics of
different immune cells expressing CD28H/B7-H5 and their
relationship with cancer prognosis. Clin Exp Immunol. 200:12–21.
2020. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Zhao Y, Zheng Q and Jin L: The role of B7
family molecules in maternal-fetal immunity. Front Immunol.
11:4582020. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Kang JH, Jung MY and Leof EB: B7-1 drives
TGF-β stimulated pancreatic carcinoma cell migration and expression
of EMT target genes. PLoS One. 14:e02220832019. View Article : Google Scholar
|
|
13
|
Byers JT, Paniccia A, Kaplan J, Koenig M,
Kahn N, Wilson L, Chen L, Schulick RD, Edil BH and Zhu Y:
Expression of the novel costimulatory molecule B7-H5 in pancreatic
cancer. Ann Surg Oncol. 22(Suppl 3): S1574–S1579. 2015. View Article : Google Scholar
|
|
14
|
Dong Z, Zhang L, Xu W and Zhang G: EGFR
may participate in immune evasion through regulation of B7-H5
expression in non-small cell lung carcinoma. Mol Med Rep.
18:3769–3779. 2018.PubMed/NCBI
|
|
15
|
Zhu Y, Yao S, Iliopoulou BP, Han X,
Augustine MM, Xu H, Phennicie RT, Flies SJ, Broadwater M, Ruff W,
et al: B7-H5 costimulates human T cells via CD28H. Nat Commun.
4:20432013. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Chen Q, Wang J, Chen W, Zhang Q, Wei T,
Zhou Y, Xu X, Bai X and Liang T: B7-H5/CD28H is a co-stimulatory
pathway and correlates with improved prognosis in pancreatic ductal
adenocarcinoma. Cancer Sci. 110:530–539. 2019. View Article : Google Scholar :
|
|
17
|
Hu C, Xu Z, Chen S, Lv H, Wang Y, Wang X,
Mo S, Shi C, Wei S, Hu L, et al: Overexpression of B7H5/CD28H is
associated with worse survival in human gastric cancer. J Cell Mol
Med. 24:1360–1369. 2020. View Article : Google Scholar :
|
|
18
|
Das AK, Sato M, Story MD, Peyton M, Graves
R, Redpath S, Girard L, Gazdar AF, Shay JW, Minna JD and Nirodi CS:
Non-small-cell lung cancers with kinase domain mutations in the
epidermal growth factor receptor are sensitive to ionizing
radiation. Cancer Res. 66:9601–9608. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Steiner P, Joynes C, Bassi R, Wang S,
Tonra JR, Hadari YR and Hicklin DJ: Tumor growth inhibition with
cetuximab and chemotherapy in non-small cell lung cancer xenografts
expressing wild-type and mutated epidermal growth factor receptor.
Clin Cancer Res. 13:1540–1551. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Trick AY, Chen FE, Schares JA, Freml BE,
Lor P, Yun Y and Wang TH: High resolution estimates of relative
gene abundance with quantitative ratiometric regression PCR
(qRR-PCR). Analyst. 146:6463–6469. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Jia Y, Li X, Jiang T, Zhao S, Zhao C,
Zhang L, Liu X, Shi J, Qiao M, Luo J, et al: EGFR-targeted therapy
alters the tumor microenvironment in EGFR-driven lung tumors:
Implications for combination therapies. Int J Cancer.
145:1432–1444. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Ni L and Dong C: New B7 family checkpoints
in human cancers. Mol Cancer Ther. 16:1203–1211. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Zhao R, Chinai JM, Buhl S, Scandiuzzi L,
Ray A, Jeon H, Ohaegbulam KC, Ghosh K, Zhao A, Scharff MD and Zang
X: HHLA2 is a member of the B7 family and inhibits human CD4 and
CD8 T-cell function. Proc Natl Acad Sci USA. 110:9879–9884. 2013.
View Article : Google Scholar : PubMed/NCBI
|
